Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Advances in OncologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Cancer facts & figures 2021.American Cancer Society, Atlanta2021
- NCCN guidelines insights: rectal cancer, version 6.2020.J Natl Compr Canc Netw. 2020; 18: 806-815
- Impact of multidisciplinary tumor boards on patients with rectal cancer.Mol Clin Oncol. 2018; 9: 135-137
- A comprehensive framework for early-onset colorectal cancer research.Lancet Oncol. 2022; 23: e116-e128
- Use of magnetic resonance imaging in rectal cancer patients: society of abdominal radiology (SAR) rectal cancer disease-focused panel (DFP) recommendations 2017.Abdom Radiol (NY). 2018; 43 (MRI guidelines): 2893-2902
- Rectal cancer MR staging: pearls and pitfalls at baseline examination.Abdom Radiol (NY). 2019; 44: 3536-3548
- Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study.BMJ. 2006; 333: 779
- MERCURY II study group. prospective validation of a low rectal cancer magnetic resonance imaging staging system and development of a local recurrence risk stratification model: The MERCURY II study.Ann Surg. 2016; 263: 751-760
- Comparison of three classifications for lymph node evaluation in patients undergoing total mesorectal excision for rectal cancer.Langenbecks Arch Surg. 2018; 403: 451-462
- Accuracy of various lymph node staging criteria in rectal cancer with magnetic resonance imaging.J Gastrointest Surg. 2018; 22: 146-153
- Preoperative versus postoperative chemoradiotherapy for rectal cancer.N Engl J Med. 2004; 351: 1731-1740
- Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer.J Clin Oncol. 2006; 24: 668-674
- Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo Cancer de Recto 3 study.J Clin Oncol. 2010; 28: 859-865
- Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial.Ann Oncol. 2015; 26: 1722-1728
- Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study.Oncologist. 2011; 16: 614-620
- Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study.Ann Oncol. 2012; 23: 1525-1530
- Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer.J Natl Compr Canc Netw. 2014; 12: 513-519
- Complete neoadjuvant treatment of rectal cancer: the Brown University Oncology Group CONTRE study.Am J Clin Oncol. 2017; 40: 283-287
- Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer.JAMA Oncol. 2018; 4: e180071
- Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial.JAMA Oncol. 2021; 7: 1225-1230
- Preliminary results of the organ preservation of rectal adenocarcinoma (OPRA) trial.J Clin Oncol. 2020; 38 (abstr 4008))
- RAPIDO collaborative investigators. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.Lancet Oncol. 2021; 22: 29-42
- Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.Lancet Oncol. 2021; 22: 702-715
- Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer.BMC Cancer. 2015; 15: 384
- Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.Lancet Oncol. 2012; 13: 1225-1233
- Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.Lancet Oncol. 2014; 15: 1481-1492
- Neoadjuvant 5-FU or capecitabine plus radiation with or without oxaliplatin in rectal cancer patients: a phase iii randomized clinical trial.J Natl Cancer Inst. 2015; 107: djv248
- Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.J Clin Oncol. 2009; 27: 3109-3116
- Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials.Lancet Oncol. 2020; 21: 1620-1629
- Timothy Iveson. Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration.J Clin Oncol. 2017; 35 (abstr LBA1))
- Overall survival (OS) and long-term disease-free survival (DFS) of three versus six months of adjuvant (adj) oxaliplatin and fluoropyrimidine-based therapy for patients (pts) with stage III colon cancer (CC): Final results from the IDEA (International Duration Evaluation of Adj chemotherapy) collaboration.J Clin Oncol. 2020; 38 (abstr 4004))
- mFOLFOXIRI versus mFOLFOX6 as neoadjuvant chemotherapy in locally advanced rectal cancer: a propensity score matching analysis.Clin Colorectal Cancer. 2021; (S1533-0028(21)00125-130)https://doi.org/10.1016/j.clcc.2021.11.009
- Intensified total neoadjuvant therapy in patients with locally advanced rectal cancer: a phase II trial.Clin Oncol (R Coll Radiol). 2021; 33: 788-794
- Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.Lancet Oncol. 2012; 13: 579-588
- Watch-and-wait management for rectal cancer after clinical complete response to neoadjuvant therapy.Adv Surg. 2021; 55: 89-107
- Postoperative complications in patients irradiated pre-operatively for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs chemoradiation.Colorectal Dis. 2005; 7: 410-416
- Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial.Lancet Oncol. 2017; 18: 336-346
- Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.N Engl J Med. 2001; 345: 638-646
- Pathologic complete response of primary tumor following preoperative chemoradiotherapy for locally advanced rectal cancer: long-term outcomes and prognostic significance of pathologic nodal status (KROG 09-01).Ann Surg. 2010; 252: 998-1004
- Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch & Wait Database: a retrospective, international, multicentre registry study.Lancet Oncol. 2021; 22: 43-50
- Assessment of a watch-and-wait strategy for rectal cancer in patients with a complete response after neoadjuvant therapy.JAMA Oncol. 2019; 5: e185896
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.N Engl J Med. 2015; 372: 2509-2520
- Mismatch repair-deficient rectal cancer and resistance to neoadjuvant chemotherapy.Clin Cancer Res. 2020; 26: 3271-3279
- Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, toward assessment of adjuvant therapy efficacy and clinical behavior of recurrences.Clin Cancer Res. 2022; 28: 507-517
- Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study.Gut. 2019; 68: 663-671
- Serial circulating tumour DNA analysis for locally advanced rectal cancer treated with preoperative therapy: prediction of pathological response and postoperative recurrence.Br J Cancer. 2020; 123: 803-810
- A rectal cancer organoid platform to study individual responses to chemoradiation.Nat Med. 2019; 25: 1607-1614
- Patient-derived cancer organoid cultures to predict sensitivity to chemotherapy and radiation.Clin Cancer Res. 2019; 25: 5376-5387
- Integrating Subclonal Response Heterogeneity to Define Cancer Organoid Therapeutic Sensitivity.bioRxiv. 2021; https://doi.org/10.1101/2021.10.15.464556
Article info
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
